Funding profile · Population genomics

Sequence Bio

A Canadian private company with about $4.0 million in announced equity from 2015 and 2016, an undisclosed Y Combinator investment in 2019, and no SEC filings. The most specific number in its capital picture is a royalty schedule it owes the province.

$4.0MAnnounced equity financing, 2015 to 2016
$3.0MLargest announced round, August 2016, led by DCVC
$300KFirst investment ever made by Venture NL, July 2015
0Form D filings on SEC EDGAR

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Jul 2015 Seed tranche $500,000 Venture Newfoundland and Labrador $300,000; the balance reported variously as an Ontario angel or as Pelorus and Klister Credit Corp Trade press
Oct 2015 Seed, closed $1.0M total Killick Capital $500,000; Pelorus Venture Capital; Klister Credit Corp Trade press and release
Aug 2016 Seed $3.0M Led by Data Collective (DCVC); Killick Capital, Venture NL, Klister Credit Corp Trade press
Summer 2019 Y Combinator, S19 Not disclosed Y Combinator Company release
Oct 2015 Provincial partnership, not capital No amount stated Government of Newfoundland and Labrador; Genospace as software partner Company release
Apr 2025 Benefits and Royalty Agreement, not capital Tiered royalty, 10 years Government of Newfoundland and Labrador Company and government

What the public record shows

Sequence Bioinformatics Inc. · seed round · announced Oct 2015

First tranche
July 2015
Announced total
$1,000,000
Named investors
Killick Capital ($500,000); Pelorus Venture Capital; Klister Credit Corp; Venture Newfoundland and Labrador ($300,000)
Discrepancy
Entrevestor describes the July tranche as $500,000 made up of Venture NL and an Ontario angel. The company release describes Pelorus and Klister investing $500,000 in June and July. Neither has been amended.
Filing
No securities filing. Canadian private issuer.

Sequence Bioinformatics Inc. · seed round · announced Aug 3, 2016

Amount
$3,000,000
Lead
Data Collective (DCVC), Silicon Valley
Participants
Killick Capital, Venture NL, Klister Credit Corp
Company claim
Described as the first investment by a Silicon Valley venture fund into Atlantic Canada
Stated need
CEO Tyler Wish told CBC the full project would require about $100 million
Filing
No securities filing. Canadian private issuer.

Reading the record

  1. The announced capital is a fraction of the stated requirement.In August 2016 the company said the 100,000 person project needed about $100 million. Announced equity at that point totalled $4.0 million, about 4 percent of it. The project as executed was a 2,500 person pilot.
  2. Absence of a Form D means nothing here.Sequence Bio is a private Canadian issuer headquartered in St. John’s. Regulation D notices apply to US offerings, and the records pull found none, alongside no FDA record, no registered trial and no US federal grant. The absence is a jurisdiction fact, not evidence about how much was raised.
  3. The company profile claims more than the announcements account for.A Y Combinator founder profile lists Sequence Bio S19 as having raised more than $10 million. Publicly announced rounds total $4.0 million plus an undisclosed YC investment. The gap of at least $6 million has no named source, and the company states that it does not release the terms of its financing.
  4. The province sits on several sides of the table.Venture NL, funded by the provincial government, BDC Capital and private investors, was an early shareholder. The province signed a precision medicine partnership in 2015 and a royalty agreement in 2025. The province also owns the Health Research Ethics Authority, whose board refused two Sequence Bio applications in 2018 and which the company then sued.
  5. Benefit sharing is priced off revenue, and starts small.The April 2025 agreement pays 1 percent of the first $5 million of gross revenue, 1.5 percent from $5 million to $25 million, and 2.0 percent at or above $25 million, with deferrals tied to profitability targets. At $25 million of revenue that is $50,000 plus $300,000, or $350,000, about 1.4 percent of the top line. No revenue has been disclosed.
  6. Control has stayed close to the original investors.Mark Dobbin, president of Killick Capital and an investor and director from 2016, is chair of the board. The chief executive has changed twice, from co-founder Tyler Wish to co-founder Chris Gardner in November 2016, and later to Lynn Healey, who was promoted from chief operating and financial officer.

Commercial signals

Signal Detail Source type
Revenue None disclosed. The royalty agreement contemplates commercial R and D revenue that has not been reported. Not found
Pharma partners No named licensing deal or pharma partnership found in public sources. Not found
Public sector contracts Named an innovation partner and vendor of record by NL Health Services, one of 11 selected. Company-stated
Scientific output Two peer reviewed population genetics papers, 2023 and 2024, using project samples. Public record
Active study Study of Genetic Causes of Inherited Disease in Newfoundland and Labrador, launched March 4, 2026, enrolling. Company-stated
Headquarters commitment The 2025 agreement commits the company to keep its headquarters and build capacity in the province for its term. Company and government

What to watch

  • Any disclosed financing after 2019. Nothing has been announced in seven years.
  • The first royalty payment, which would be the first public confirmation of revenue.
  • Whether DCVC or Killick Capital marks the position, or a new lead appears.
  • Enrollment totals for the 2026 study, the number the earlier project stopped reporting.

The Sequence Bio story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Helix Nanotechnologies: Shared investor: Data Collective. An mRNA company that started on cancer, turned to COVID-19 in one week of March 2020, and took a single vaccine candidate into a first human study in Australia
  • Kenota: Shared investor: Bdc Capital. A Kitchener, Ontario company that spent a decade trying to make allergy testing faster than a trip to the allergist
  • Transcriptic: Shared investor: Data Collective. The first robotic cloud laboratory for the life sciences, started in 2012 by a Duke undergraduate who was tired of pressing a button on a plate reader
  • Culture Biosciences: Shared investor: Data Collective. A cloud lab that ran other companies’ fermentation for them, now selling the bioreactor itself through Cytiva

Sources

  1. Public recordRecords pull: no SEC Form D, no FDA record, no registered trial, no NIH or NSF awardProfile records file · Sep 2026
  2. IndependentVenture NL Invests $300K in SequenceEntrevestor · 2015
  3. IndependentSequence Bio raises $1 million seed, partners with Newfoundland and Labrador governmentBetaKit · Oct 20, 2015
  4. IndependentSequence Bio raises $3 million in round led by Silicon Valley-based DCVCBetaKit · Aug 4, 2016
  5. IndependentSilicon Valley firm invests big bucks in St. John’s company Sequence BioCBC News · Aug 3, 2016
  6. IndependentSequence Bio CEO steps down from role as co-founder takes overBetaKit · Nov 24, 2016
  7. IndependentN.L. Supreme Court judge rules Sequence Bio case against regulator can proceedThe Telegram · Jun 15, 2018
  8. CompanySequence Bio announces major precision medicine partnership with the Government of Newfoundland and LabradorCNW · Oct 16, 2015
  9. CompanySequence Bio enters into a Benefits and Royalty Agreement with the Government of Newfoundland and LabradorSequence Bio · Apr 29, 2025
  10. CompanySequence Bio receives investment from Y CombinatorSequence Bio · 2019
  11. CompanyY Combinator company and founder profile, Sequence BioY Combinator · accessed Sep 24, 2026
  12. CompanyNL Health Services selects Sequence Bio as an Innovation PartnerSequence Bio

Compiled from Canadian court, legislative and government records, peer reviewed journals, SEC EDGAR searches and published reports as of September 22, 2026. Sequence Bio is a private Canadian issuer and files no Form D; announced round amounts are as reported at the time and may not reflect final closes. Healthcare Venture Capital Fund holds no position in Sequence Bio. This page is not an offer to sell or a recommendation to buy any security.